Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001193125-16-567757
Filing Date
2016-04-29
Accepted
2016-04-29 13:07:01
Documents
7
Effectiveness Date
2016-04-29

Document Format Files

Seq Description Document Type Size
1 DEFA14A d178605ddefa14a.htm DEFA14A 46915
2 GRAPHIC g178605notice01a.jpg GRAPHIC 4607
3 GRAPHIC g178605notice01b.jpg GRAPHIC 2068
4 GRAPHIC g178605notice02a.jpg GRAPHIC 3662
5 GRAPHIC g178605notice02b.jpg GRAPHIC 2049
6 GRAPHIC g178605notice03.jpg GRAPHIC 2079
7 GRAPHIC g178605notice04.jpg GRAPHIC 2079
  Complete submission text file 0001193125-16-567757.txt   71827
Mailing Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158
Business Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158 4154825300
NEKTAR THERAPEUTICS (Filer) CIK: 0000906709 (see all company filings)

EIN.: 943134940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 000-24006 | Film No.: 161604666
SIC: 2834 Pharmaceutical Preparations